P glycoprotein in human immunodeficiency virus type 1 infection and therapy

Abstract:

With the advent and widespread use of potent antiretroviral therapy in the mid-1990s, the clinical course of human immunodeficiency virus (HIV) type 1 (HIV-1) infection has changed dramatically in a substantial proportion of HIV-1-infected individuals. This has led to a significant decline in the incidence of AIDS and AIDS-related morbidity and mortality in the developed world (30, 84, 96, 102). Protease inhibitors in combination with inhibitors of HIV-1 reverse transcriptase cause a dramatic reduction in plasma viremia, with the plasma HIV-1 RNA load being below the limit of detection in many patients (52, 56). However, with the currently available drugs, complete eradication of HIV-1 from an infected person is not achieved because of the persistence of latently infected, resting CD4 T cells harboring replication-competent HIV-1 and because of ongoing low-level viral replication (23, 24, 33, 42, 45, 117, 150, 153). One …

Año de publicación:

2004

Keywords:

Fuente:

google